文献速递MDS 与骨髓增殖性肿瘤

干扰素α与羟基脲治疗真性红细胞增多症和原发性血小板增多症的随机3期试验

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
PubMed 文献 · Blood · 2022-01-01

本研究为研究者发起的3期试验,比较羟基脲(HU)与聚乙二醇干扰素α(PEG)在未治疗的高危原发性血小板增多症(ET)/真性红细胞增多症(PV)患者中的疗效,主要终点为12个月完全缓解(CR)率。168例患者中,HU组CR为37%,PEG组为35%(P=.80),无显著差异;PEG在24个月时JAK2V617F降低更明显,但HU组织病理学缓解更常见。两组血栓事件和疾病进展均少见,PEG组3/4级不良事件更频繁(46% vs 28%)。

要点

  • 12个月CR率HU组37% vs PEG组35%(P=.80),无显著差异。
  • PEG组24个月JAK2V617F降低更明显,HU组组织病理学缓解更常见。
  • 两组血栓事件和疾病进展均少见,PEG组3/4级不良事件更频繁(46% vs 28%)。

核心结论

  • 在12个月治疗时,HU与PEG的CR率无显著差异,PEG和HU均为PV和ET的有效治疗。
  • 随治疗时间延长,PEG在使血细胞计数正常化和降低驱动突变负荷方面更有效,而HU产生更多组织病理学缓解。
  • 尽管存在这些差异,两种药物在限制高危ET/PV患者血栓事件和疾病进展方面无差异。

研究设计与样本

  • Myeloproliferative Disorders Research Consortium 112为研究者发起的3期试验,比较HU与PEG在未治疗的高危ET/PV患者中的疗效。
  • 共168例患者接受治疗,中位治疗81.0周,主要终点为12个月完全缓解(CR)率。
  • 试验注册于www.clinicaltrials.gov,编号#NCT01259856。

主要发现

  • 12个月CR率HU组37% vs PEG组35%(P=.80)。
  • 24至36个月CR率HU组20%至17% vs PEG组29%至33%。
  • PEG组24个月JAK2V617F降低更明显,但HU组组织病理学缓解更频繁。
  • 两组血栓事件和疾病进展均少见,PEG组3/4级不良事件更频繁(46% vs 28%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera (PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and interferon-α (IFN-α) are the most frequently used cytoreductive options for patients with ET and PV at high risk for vascular complications. Myeloproliferative Disorders Research Consortium 112 was an investigator-initiated, phase 3 trial comparing HU to pegylated IFN-α (PEG) in treatment-naïve, high-risk patients with ET/PV. The primary endpoint was complete response (CR) rate at 12 months. A total of 168 patients were treated for a median of 81.0 weeks. CR for HU was 37% and 35% for PEG (P = .80) at 12 months. At 24 to 36 months, CR was 20% to 17% for HU and 29% to 33% for PEG. PEG led to a greater reduction in JAK2V617F at 24 months, but histopathologic responses were more frequent with HU. Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%). At 12 months of treatment, there was no significant difference in CR rates between HU and PEG. This study indicates that PEG and HU are both effective treatments for PV and ET. With longer treatment, PEG was more effective in normalizing blood counts and reducing driver mutation burden, whereas HU produced more histopathologic responses. Despite these differences, both agents did not differ in limiting thrombotic events and disease progression in high-risk patients with ET/PV. This trial was registered at www.clinicaltrials.gov as #NCT01259856.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood. 2022. PMID: 35007321. doi:10.1182/blood.2021012743

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。